Viking Therapeutics, Inc. (NASDAQ:VKTX) will be issuing its quarterly earnings data after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). On average, analysts expect Viking Therapeutics to post $-0.83 EPS for the current fiscal year and $-0.80 EPS for the next fiscal year.

Viking Therapeutics, Inc. (NASDAQ:VKTX) opened at 2.38 on Wednesday. Viking Therapeutics, Inc. has a one year low of $0.88 and a one year high of $3.24. The firm’s market capitalization is $65.92 million. The stock’s 50 day moving average price is $1.97 and its 200-day moving average price is $1.95.

A number of research firms have weighed in on VKTX. Maxim Group restated a “buy” rating and issued a $5.00 price target on shares of Viking Therapeutics in a research note on Wednesday, October 4th. ValuEngine upgraded Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 target price (up from $5.00) on shares of Viking Therapeutics in a research note on Monday, July 17th.

WARNING: “Viking Therapeutics, Inc. (VKTX) Set to Announce Quarterly Earnings on Wednesday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Earnings History for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with's FREE daily email newsletter.